The Ambry CARE Program® brings accurate, personalized breast cancer risk assessments directly into clinical workflows helping direct patients at high risk for breast cancer to seek additional ...

Peer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool validated with real-world patient data ...

Tempus AI Inc. (NASDAQ:TEM) is one of the best AI stocks to buy according to hedge funds. On June 25, Ambry Genetics, which is a wholly owned subsidiary of Tempus AI, announced the publication of a ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...

In hopes of gifting researchers a tool they can use to identify links between genes and disease, Viejo, Calif.-based DNA testing firm Ambry Genetics made public a database containing the information ...

New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary cancer predisposition. Ambry Genetics, a ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...

New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary cancer predisposition. PALB2 is one of the ...

Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the completion of its one-millionth DNA/RNA test, underscoring the ...